Table 3 |
||
|
Serological parameters in PR3/MPO-ANCA-positive idiopathic vasculitides and antithyroid DIDs |
||
| Patients with idiopathic vasculitides (n = 56) |
Patients with antithyroid DIDs (n = 16) |
|
|
|
||
| pANCA |
28 (50) |
15 (94)** |
| Median (1/titer) |
64 |
256* |
| Range (1/titer) |
32–256 |
64–512 |
| MPO-ANCA |
29 (52) |
15 (94)** |
| MPO-ANCA (U/ml) |
64.3 ± 22 |
55 ± 19 |
| CANCA |
28 (50) |
1(6)** |
| Median (1/titer) |
64 |
64 |
| Range (titer) |
1:32–1:256 |
- |
| PR3-ANCA |
27 (48) |
1 (6)** |
| PR3-ANCA (U/ml) |
58.8 ± 17 |
44 |
| ANA |
3 (5) |
8 (50)*** |
| Median (1/titer) |
40 |
80 |
| Anti-DNA |
0 |
1 (6) |
| Anti-histone |
0 |
3(19)** |
| Anti-SSA |
0 |
1(6) |
| aCL |
6 (11) |
9 (56)*** |
| IgG |
5 (9) |
1 (6) |
| IgM |
0 |
2 (12.5)* |
| IgG/IgM |
1 (2) |
6 (37.5)*** |
| Anti-β2 GP I |
2 (3.5) |
4 (25)* |
| IgG |
1 (2) |
1 (6) |
| IgM |
1 (2) |
3 (19)* |
| Cryoglobulinemia |
0 |
3 (19)** |
| Antimicrosomal Ab |
1 (2) |
13 (81)*** |
| Antithyroglobulin Ab |
1 (2) |
3 (19)* |
| Low C4 (<0.1 g/l) |
0 |
3 (19)** |
| Low α1 AT (<1.1 g/l) |
13 (23) |
0 |
| High CR-P (>10 mg/l) |
56 (100) |
8 (50)*** |
| CR-P mg/l |
90 ± 35 |
46 ± 15** |
| Leucopenia (<3 × 109/l) |
1 (2) |
2 (12.5) |
|
|
||
|
All values represent either numbers of patients (%), or mean ± standard deviation, except median and range for p and cANCA titer. *p <0.05, **p < 0.01, ***p < 0.001. α1 AT, alpha-1 antitrypsin; Ab, antibodies; aCL, anticardiolipin antibodies; ANA, antinuclear antibodies; anti-β2 GP I, anti-beta 2 glycoprotein I; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CR-P, C reactive protein; DID, drug-induced autoimmune disease; MPO, myeloperoxidase; pANCA, perinuclear antineutrophil cytoplasmic antibodies; PR3, proteinase 3. |
||
|
Bonaci-Nikolic et al. Arthritis Research & Therapy 2005 7:R1072 doi:10.1186/ar1789 |
||
